Welcome to our dedicated page for Summit Therapeutics news (Ticker: SMMT), a resource for investors and traders seeking the latest updates and insights on Summit Therapeutics stock.
Summit Therapeutics Inc. (NASDAQ: SMMT) is a biopharmaceutical oncology company whose news flow is closely tied to the development of its lead investigational therapy, ivonescimab (SMT112 in Summit’s territories). Ivonescimab is described by the company as a potential first-in-class bispecific antibody targeting PD-1 and VEGF in a single molecule, and it is being evaluated in multiple Phase III clinical trials in non-small cell lung cancer (NSCLC) and colorectal cancer (CRC).
News about Summit frequently covers clinical milestones for ivonescimab, including updates from the global Phase III HARMONi trial in EGFR-mutated NSCLC after third-generation EGFR TKI therapy, as well as HARMONi-3 and HARMONi-7 in first-line metastatic NSCLC and HARMONi-GI3 in first-line unresectable metastatic CRC. Company announcements have highlighted progression-free survival and overall survival data, hazard ratios, response rates, and safety profiles, along with presentations at major conferences such as the World Conference on Lung Cancer, SITC, and ESMO.
Investors following SMMT news will also see regulatory and corporate updates, including Summit’s submission of a Biologics License Application to the U.S. FDA for ivonescimab plus chemotherapy in EGFR-mutated NSCLC, Fast Track designation for the HARMONi setting, and summaries of Akeso’s HARMONi-A trial in China, which demonstrated a statistically significant overall survival benefit for ivonescimab plus chemotherapy versus chemotherapy alone.
Additional news items cover financing activities such as private placements and at-the-market offerings, inducement stock option grants under Nasdaq Listing Rule 5635(c)(4), and collaboration announcements. Notably, Summit has reported a clinical trial collaboration with GSK plc to evaluate ivonescimab in combination with GSK’s investigational B7-H3-targeting antibody-drug conjugate, risvutatug rezetecan (GSK’227), across multiple solid tumor settings including small cell lung cancer.
For readers tracking SMMT, the news stream provides insight into Summit’s late-stage oncology pipeline, regulatory interactions, capital-raising efforts, and partnerships that shape the company’s development path.
Summit Therapeutics (NASDAQ:SMMT) announced updated results from the global Phase III HARMONi trial for ivonescimab, a novel PD-1/VEGF bispecific antibody. The trial demonstrated an improved overall survival (OS) hazard ratio of 0.78 with a nominal p-value of 0.0332. The median OS was 16.8 months for ivonescimab plus chemotherapy versus 14.0 months for placebo plus chemotherapy.
Key findings include statistically significant progression-free survival (PFS) with a hazard ratio of 0.52 (p0.00001), and higher overall response rates in the ivonescimab arm (45%) compared to placebo (34%). North American patients showed particularly strong results with an OS hazard ratio of 0.70. The drug demonstrated consistent benefits across Western and Asian populations, with a favorable safety profile.
Summit Therapeutics (NASDAQ:SMMT) announced updated data from its Phase III HARMONi trial for ivonescimab plus chemotherapy in EGFR-mutated NSCLC patients. In the longer-term follow-up analysis of Western patients, the treatment showed an improved overall survival (OS) trend with a nominal p-value of 0.0332 versus chemotherapy alone.
Key findings include median OS of 16.8 months for ivonescimab plus chemotherapy vs. 14.0 months for placebo plus chemotherapy. North American patients showed particularly promising results with OS hazard ratio of 0.70. The treatment demonstrated statistically significant progression-free survival (PFS) improvement with hazard ratio of 0.52 (p0.00001)45% vs. 34% for placebo.
The safety profile remained manageable with 7.3% discontinuation rate due to treatment-related adverse events.
Summit Therapeutics (NASDAQ: SMMT) has announced a conference call on September 8, 2025, at 8:00 AM ET to discuss data from their Phase III clinical trial, HARMONi. The presentation will be featured in the Presidential Symposium at the 2025 World Conference on Lung Cancer (WCLC) in Barcelona.
The HARMONi trial is evaluating ivonescimab plus platinum-doublet chemotherapy versus placebo in patients with EGFR-mutated non-small cell lung cancer (NSCLC) who have progressed after treatment with 3rd generation EGFR TKI. The presentation will be accessible through Summit's website, with an archived version available afterward.
Summit Therapeutics (NASDAQ: SMMT) announced that data from their Phase III HARMONi trial of ivonescimab will be presented at the WCLC 2025 Presidential Symposium on September 7, 2025. The trial evaluated ivonescimab plus chemotherapy versus placebo in EGFR-mutated non-small cell lung cancer (NSCLC) patients.
The study demonstrated statistically significant improvement in progression-free survival with a hazard ratio of 0.52 (p<0.00001). While overall survival showed a positive trend with a hazard ratio of 0.79, it did not reach statistical significance (p=0.057). The presentation will be delivered by Dr. Jonathan Goldman from UCLA, marking ivonescimab's second consecutive year at the WCLC Presidential Symposium.
Summit Therapeutics (NASDAQ:SMMT) reported significant progress in Q2 2025, highlighted by positive results from multiple Phase III trials of ivonescimab. The HARMONi trial demonstrated statistically significant improvement in progression-free survival with a hazard ratio of 0.52 (p<0.00001) in EGFR-mutated NSCLC patients.
The company's financial position showed $297.9 million in cash and investments as of June 30, 2025, down from $412.3 million in December 2024. A significant non-cash expense of $466.6 million was recorded due to stock option modifications. The company established a new $360 million ATM offering facility with J.P. Morgan.
Key operational highlights include positive interim survival analysis in the HARMONi-2 study, NMPA approval in China for first-line PD-L1 positive advanced NSCLC, and a new clinical collaboration with Revolution Medicines for RAS(ON) inhibitor combinations.
Summit Therapeutics (NASDAQ: SMMT) has announced inducement grants of stock options to nine new employees. The options collectively allow for the purchase of up to 94,050 shares of common stock at an exercise price of $22.75 per share, which was the closing price on May 14, 2025. The options have a ten-year term and will vest in equal annual installments over a four-year period. These grants were approved by Summit's Compensation Committee and were awarded in accordance with Nasdaq Listing Rule 5635(c)(4), which allows for inducement grants to new employees.